Actively Recruiting
Evaluating Safety and Dose Effects of Nebulized CSL787 in Adults 18 to 85 With Non-cystic Fibrosis Bronchiectasis
Led by CSL Behring · Updated on 2026-10-19
180
Participants Needed
13
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of CSL787, a human normal immunoglobulin G IgG inhalation solution, in adults with Non-cystic Fibrosis Bronchiectasis NCFB. This proof-of-concept phase 2b study is randomized, double-blind, placebo-controlled, and aims to explore the efficacy, safety, and tolerability of two different doses of nebulized CSL787 compared with placebo over a 52-week period. The main goal is to understand how CSL787 affects the time to the first exacerbation in participants with NCFB. Participants will be randomly assigned to receive either a high dose or a low dose of CSL787 inhaled once daily via nebulizer, or a matching placebo, for up to 52 weeks. The nebulizer device used is CE-marked. The study includes three arms high dose CSL787, low dose CSL787, and placebo. The treatment period lasts for 52 weeks, during which participants will receive daily inhalation treatments corresponding to their assigned group. During the study, participants will be closely monitored with various assessments including lung function tests, sputum collection for bacterial analysis, quality of life questionnaires focused on respiratory symptoms, and recording of any exacerbations or adverse events. Researchers will measure the time to first exacerbation, number of exacerbations, changes in respiratory symptoms, and safety outcomes up to 56 weeks. Participation involves regular visits and evaluations to assess treatment effects and monitor safety throughout the study duration.
CONDITIONS
Brief Title
Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)
Research Team
T
Trial Registration Coordinator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here